Skip to content
DataLookout
Menu

NCT07927491

Surgical Window Study of CM93 in Subjects With Recurrent Glioblastoma (rGBM)

StatusNot Yet Recruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Part 1: Number of Dose-limiting toxicities (DLTs) observed
Timeframe: From the first study treatment until the 30-Day Post Drug Visit
Part 2: Concentration of CM93 in non-enhancing areas of the tumor
Timeframe: Day of Surgery (up to 2 weeks)

Secondary (7)

Part 1: Area under the curve (AUC)
Part 1: Maximum plasma concentration (Cmax)
Part 1: Trough plasma concentration (Cmin)
Part 1: Time to maximum plasma concentration (Tmax)
Part 1: Plasma half-life (T1/2)
Show 2 moreShow less
Part 2: Concentration of CM93 in enhancing areas of the tumor
Part 2: Inhibition of epidermal growth factor receptor (EGFR) as determined by Phosphorylated Epidermal Growth Factor Receptor (p-EGFR) levels

Arms and interventions

Part 1: Dose Escalation and Expansion PhaseExperimental

CM93 monotherapy dose escalation for participants with recurrent glioblastoma (rGBM) characterized by EGFR amplification/mutation at different doses of the study drug, starting at 40 mg and up to 480 mg.

Part 2: CM93-pre-treated cohortExperimental

CM93 monotherapy pre-treatment prior to surgical resection for approximately 1 week, and then daily treatment with CM93 at least 14 days following surgery.

Part 2: Control (no pre-treatment)Active comparator

No pre-treatment prior to surgical resection, and then daily treatment with CM93 at least 14 days following surgery.

Drugs: CM93

Sites

3 sites in 1 country